Navigation Links
Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
Date:7/1/2010

CAMBRIDGE, Mass., July 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease.  The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

A post-hoc analysis was undertaken of TKT-025 EXT to evaluate the achievement of long-term therapeutic goals, including improvement in bone mineral density (BMD), among all 8 type 1 treatment naive Gaucher patients who participated in TKT-025 EXT and were treated for a minimum of 48 months.  The initial dose of 60 U/kg administered intravenously every other week (EOW) was lowered in a step-wise fashion to 45 U/kg EOW and then to 30 U/kg EOW after patients achieved at least 2 of 4 predefined therapeutic goals following 1 year of treatment.  Seven of the 8 patients were maintained at the lower dose.  All of the patients achieved the therapeutic goals for hemoglobin concentrations, platelet counts, liver and spleen volumes, and improvement in BMD within 4 years of initiation of treatment with VPRIV.

A separate post-hoc analysis of the change in BMD among patients in TKT-025 EXT through 69 months was also reported.  All intent to treat (ITT) patients (n=10) had type 1 Gaucher disease-related bone issues such as osteoporosis and osteopenia at baseline.  Changes in BMD were monitored
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Global ENT (Ear, Nose, And ... 23.01 million in 2022, according to a new study ... population, increasing prevalence of ear, nose, and throat related ... target customer base are expected serve this market as ... to estimates published by the WHO, 15% of adult ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud ... predictive analytics technology, announces it is working with ... solutions for the new Lockheed Martin Healthcare Technology ... leading health information technology providers, medical technology companies ... collaboration and innovation to improve care in rapidly ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 13, 2007 -,Cytos Biotechnology AG (SWX:CYTN) reported ... with CYT003-QbG10, an immunotherapeutic,product candidate for the ... patients suffering from mild to moderate allergic,rhinitis ... The trial,investigated in a doubleblind setting the ...
... company Pharmaxis today announced the results,from its Phase ... Pulmonary Disease (COPD), a respiratory disease,affecting over 30 ... in 79 diagnosed COPD patients at 12,centres in ... to,determine if subjects that were positive to an ...
Cached Medicine Technology:Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4
(Date:7/31/2015)... Nashville, TN (PRWEB) , ... July 31, 2015 ... ... Nashville, Tenn. has launched a Balloon Sinuplasty website to inform potential Nashville ... includes a questionnaire that can be used to determine if someone is a ...
(Date:7/30/2015)... ... July 30, 2015 , ... Dale Sky Jones, Executive Chancellor of Oaksterdam ... International Cannabis Professionals Expo held at the Caribe Royal All Suites Hotel and Convention ... Expo is the largest medical cannabis expo in the country and this year’s ...
(Date:7/30/2015)... ... , ... On July 22nd the Bradenton Herald reported the Opioid ... controlling the heroin outbreak. Ultimately the committee expressed lack of funding, and the absence ... crisis in North Florida. The task force has proposed to instate counselors to meet ...
(Date:7/30/2015)... , ... July 30, 2015 , ... As more hospitals ... activity of recruiting patients becomes a serious challenge. Because of growing competition, it ... patients within the local community. , The team at Wound Care Advantage ...
(Date:7/30/2015)... ... 2015 , ... In an effort to provide the twenty four hour continuous ... in his practice. , The decision will also allow him to spend more time ... transferring his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has ...
Breaking Medicine News(10 mins):Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2
... , FRIDAY, Jan. 20 (HealthDay News) -- Rapid ... with an increased risk of asthma symptoms in preschool children, ... infancy might be a critical period for the development of ... Netherlands. They examined data collected from 5,125 children who ...
... non-intubated,patients may be an effective strategy for bridging patients ... Germany. "As waiting times for donor organs continue ... for patients with end-stage lung disease awaiting transplantation," said ... Hannover Medical School in Hannover, Germany. "Our study shows ...
... Shortages of key drugs used to fight infections represent ... risk, according to a review published in Clinical ... anti-infective shortages can substantially alter clinical care and may ... development of new anti-infectives has slowed and the prevalence ...
... , THURSDAY, Jan. 19 (HealthDay News) -- Allowing homeless ... were provided with housing actually decreased their heavy drinking by ... found. The study, published in the Jan. 19 issue ... included residents of a program called project-based Housing First, which ...
... aggressive and spread they are the most deadly. Unfortunately, ... A new imaging platform developed by Lawson Health Research ... insight into just that - the exact moment when ... E-cadherin, are important for the maintenance of normal tissue ...
... With a growing need for family-friendly workplace policies, ... Women & Families, with support from the Rockefeller Foundation, ... to positive economic outcomes for working families, businesses and ... for Women and Work at Rutgers, the State University ...
Cached Medicine News:Health News:Rapid Infant Growth Linked to Asthma in Study 2Health News:Extracorporeal membrane oxygenation as a bridge to lung transplantation 2Health News:Anti-infective drug shortages pose threat to public health and patient care 2Health News:Alcohol OK in Housing for Formerly Homeless, Study Says 2Health News:Lawson researchers engineer a switch to tame aggressive cancers 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: